CSI Market
Sign In | Register

Emmaus Life Sciences Inc (EMMAW) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access EMMAW Annual Cash Flow →
This page allows investors to follow Emmaus Life Sciences Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income-7.49
Depreciation & amortization0.04
Amortization of Other Assets0.56
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.02
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.03
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction1.33
Issuance Of Warrants For Financing Services-
Derivative Gain Loss On Derivative Net-
Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest-
Amortization Of Debt Discount On Bridge Notes-
Increase Decrease In Deferred Compensation Exchange For Common Stock-
Induced Conversion Of Convertible Debt Expense-
Embedded Derivative Gain Loss On Embedded Derivative Net-
Derivative Loss On Derivative-
Note Issued For Litigation Settlement-
Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount-
Foreign Exchange Adjustments On Convertible Notes And Notes Payable-
Equity Securities Fv Ni Realized Gain Loss-
Inventory Reserve0.00
Debt Securities Available For Sale Unrealized Gain Loss-
Equity Securities Fv Ni Realized Gain Loss Excluding Impairment Loss-
Gains Losses On Restructuring Of Debt-
Gain Loss On Warrant Derivative Liabilities0.01
Tax Benefit Recognized On Unrealized Gain On Debt Securities-0.59
Increase Decrease In Operating Lease Liability0.53
Gain Loss On Sale Of Loss On Leased Assets-0.86
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.18
Increase (Decrease) in Accounts Payable and Accrued Liabilities6.46
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.14
Other Working Capital0.14
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.37
Discontinued operations0.00
Net Cash flow from Operating Activities-0.01
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Costs Incurred To Develop Intangible Assets-
Payment To Loan Advance Plotkin-
Forgiveness Of Loan In Relation Of Acquisition-
Payment For Capital Contributions And Loan To Equity Method Investees-
Payments For Purchase Of Convertible Debt-
Loan To Equity Method Investee-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments2.17
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Gross0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities2.17
Financing Activities
Short-term debt Net7.91
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-9.33
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Prepaid Offering Costs-
Repayment Of Convertible Debt With Accrued Interest-
Net Proceeds From Secured Convertible Notes-
Net Proceeds From Subordinated Convertible Notes-
Net Proceeds From Unsecured Convertible Notes-
Net Proceeds From Unpefected Senior Convertible Promissory Notes-
Payement To Offering Costs Aspire Line-
Proceeds From Issuance Of Common Stock-
Repayment of Deferred Offering Costs-
Proceeds From Aspire Capital Purchase Agreements-
Payments For Repurchase Of Common Stock And Warrants-
Proceeds From Related Party Convertible Debt-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-1.43
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.01
Total Cash Flow0.74
4 historic quarters locked

Sign in to unlock the full Emmaus Life Sciences Inc cash flow history.

Sign In Create Free Account

About Emmaus Life Sciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-351833

Figures are derived from filed reports and may be restated. Historical data is subject to revision.